Perkins Coie Trust Co Grows Stock Position in Eli Lilly and Company (NYSE:LLY)

Perkins Coie Trust Co increased its stake in Eli Lilly and Company (NYSE:LLY) by 2.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,914 shares of the company’s stock after acquiring an additional 156 shares during the period. Eli Lilly and Company comprises about 1.2% of Perkins Coie Trust Co’s holdings, making the stock its 26th largest holding. Perkins Coie Trust Co’s holdings in Eli Lilly and Company were worth $5,239,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Visionary Wealth Advisors raised its holdings in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Visionary Wealth Advisors now owns 1,872 shares of the company’s stock valued at $1,091,000 after acquiring an additional 49 shares in the last quarter. Hancock Whitney Corp raised its position in shares of Eli Lilly and Company by 21.0% in the 4th quarter. Hancock Whitney Corp now owns 35,612 shares of the company’s stock worth $20,759,000 after acquiring an additional 6,174 shares in the last quarter. Northwest Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 30.8% in the 4th quarter. Northwest Wealth Management LLC now owns 895 shares of the company’s stock valued at $522,000 after purchasing an additional 211 shares during the period. Vista Investment Management bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $201,000. Finally, Ethic Inc. raised its holdings in Eli Lilly and Company by 3.2% in the fourth quarter. Ethic Inc. now owns 62,512 shares of the company’s stock worth $36,440,000 after purchasing an additional 1,940 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY stock traded up $2.06 during trading on Wednesday, reaching $915.78. The stock had a trading volume of 356,428 shares, compared to its average volume of 3,012,222. The firm has a market cap of $870.36 billion, a PE ratio of 134.57, a PEG ratio of 2.78 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock’s 50 day moving average is $904.41 and its two-hundred day moving average is $850.31. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Citigroup initiated coverage on Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.